Domp

Dompé U.S. is a biotech pharmaceutical company focused on developing innovative therapies for rare and debilitating conditions. The company leverages advanced scientific approaches, including the engineering of recombinant human nerve growth factor (rhNGF) and the utilization of its virtual screening platform, Exscalate, to accelerate drug discovery. This technical focus enables the creation of targeted treatments for complex diseases, primarily within ophthalmology and neurology.

The company's origins date back to Milan, where Gian Antonio Dompé, a pharmaceutical chemistry expert, established the family's roots in the field. His son, Onorato Dompé, founded the Dompé-Adami pharmaceutical production laboratory and later expanded into drug manufacturing. The legacy continued through Onorato's son, Franco Dompé. Decades later, Sergio Dompé, Franco's son, spearheaded a strategic shift towards biotechnology, establishing Dompé Biotec to focus on advanced biopharmaceutical solutions.

Dompé U.S. serves patients with high unmet medical needs, specifically addressing conditions such as neurotrophic keratitis, non-arteritic anterior ischemic optic neuropathy, and cerebral palsy. The company’s overarching vision is to translate complex scientific challenges into life-changing treatments, continually striving to pioneer innovative therapies across ophthalmic, neurological, and pain-related therapeutic areas, thereby improving patient outcomes globally.